Government's Role


Lilly is partnering with governments, non-government organizations and trade associations to strengthen, enact and enforce anti-counterfeiting laws, and to raise awareness of this important public health issue. Lilly encourages organizations and governmental regulatory agencies to speak up about the counterfeit drug threats they encounter. Lilly also is joining forces with non-governmental organizations such as the World Health Organization, World Health Professionals Association, Project Hope, World Customs Organization, International Federation of Pharmaceutical Manufacturers Association, Pharmaceutical Research Manufacturers Association, European Federation of Pharmaceutical Industries and others to alert patients, health care providers and government officials about alarming global trends in counterfeit medicine distribution. Increasing awareness is critical to combating the growing technological sophistication and capabilities of today’s counterfeiters.

In March 2013, INTERPOL and 29 of the world’s leading pharmaceutical companies joined forces to launch a landmark agreement to combat counterfeit medicines. The three-year initiative is funded by an investment of nearly $5.9 million combined from the companies involved, and is designed to forge strong partnerships between law enforcement and industry to enhance the global response to pharmaceutical crime.

The INTERPOL program targets multiple issues, including combating branded and generic drug counterfeiting as well as the identification and dismantling of organized crime networks linked to this illegal activity. Lilly was a leader in the formation of this important public-private partnership.

Please enable your browser's JavaScript setting in order to access this site